Oruka Therapeutics (NASDAQ:ORKA) Given “Outperform” Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report released on Tuesday morning,RTT News reports. They currently have a $40.00 price objective on the stock. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($2.46) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.94) EPS.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, October 31st. TD Cowen assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating for the company. Leerink Partners began coverage on Oruka Therapeutics in a report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price objective on the stock. Stifel Nicolaus started coverage on Oruka Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $49.00 target price for the company. Finally, Lifesci Capital began coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Oruka Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $43.17.

Oruka Therapeutics Stock Up 5.5 %

Shares of Oruka Therapeutics stock opened at $22.30 on Tuesday. Oruka Therapeutics has a 52-week low of $18.72 and a 52-week high of $53.88. The stock has a market capitalization of $26.98 million, a P/E ratio of -3.48 and a beta of 0.87. The business has a 50 day moving average price of $26.62.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company acquired a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $1,037,000. FMR LLC purchased a new stake in Oruka Therapeutics in the 3rd quarter valued at $114,763,000. Great Point Partners LLC acquired a new stake in Oruka Therapeutics during the 3rd quarter worth $12,614,000. Braidwell LP purchased a new position in Oruka Therapeutics during the 3rd quarter worth $12,640,000. Finally, Janus Henderson Group PLC acquired a new position in Oruka Therapeutics in the third quarter valued at $5,840,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.